MANNKIND CORP Contracts & Agreements

142 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
the risk of severe hypoglycemia, which is abnormally low levels of blood glucose that result from excessive insulin administration. Hypoglycemia can result in loss of mental...
Administration Agreements
MANNKIND CORP
Biotechnology
NY
2009
Second Amendment to Supply Agreement, dated November 9, 2016, by and between MannKind and Amphastar Pharmaceuticals, Inc
Supply Agreements
MANNKIND CORP
2024
Third Amendment to Supply Agreement, dated April 11, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc
Supply Agreements
MANNKIND CORP
2024
Research Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics Corporation
MANNKIND CORP
2024
Offer Letter, dated March 25, 2024, between MannKind Corporation and Chris Prentiss
MANNKIND CORP
2024
Description of Common Stock
Stock Agreements
MANNKIND CORP
2024
Offer Letter, dated May 16, 2023, by and between MannKind Corporation and Sanjay Singh
MANNKIND CORP
2024
Offer Letter, dated September 19, 2022, by and between MannKind Corporation and Burkhard Blank
MANNKIND CORP
2024
License and Collaboration Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics
Collaboration Agreements
MANNKIND CORP
2024
MannKind Corporation 2018 Equity Incentive Plan Adopted by the Board of Directors: February 21, 2018 Approved by the Stockholders: May 16, 2018 Amended by the Board of Directors:...
Bonus & Incentive Agreements
MANNKIND CORP
2023
MannKind Corporation 2004 Employee Stock Purchase Plan Adopted by the Board of Directors March 23, 2004 Approved by Stockholders March 23, 2004 Amended by the Board of Directors...
Stock Agreements
MANNKIND CORP
2023
Offer Letter, dated March 21, 2023, by and between MannKind Corporation and Lauren M. Sabella
MANNKIND CORP
Biotechnology
2023
Amendment No. 8 to Credit and Security Agreement, dated November 3, 2021, by and among MannKind Corporation, MannKind LLC, QrumPharma, Inc., and MidCap Financial Trust
Credit Agreements
MANNKIND CORP
Biotechnology
CA
2023
Amendment No. 9 to Credit and Security Agreement, dated November 8, 2021, by and among MannKind Corporation, MannKind LLC, QrumPharma, Inc., and MidCap Financial Trust
Credit Agreements
MANNKIND CORP
2023
Second Amendment to Commercial Supply Agreement, dated June 15, 2022, by and between MannKind Corporation and United Therapeutics Corporation
Supply Agreements
MANNKIND CORP
Biotechnology
2023
Third Amendment to Commercial Supply Agreement, dated August 31, 2022, by and between MannKind Corporation and United Therapeutics Corporation
Supply Agreements
MANNKIND CORP
2023
Fourth Amendment to Commercial Supply Agreement, dated December 22, 2022, by and between MannKind Corporation and United Therapeutics Corporation
Supply Agreements
MANNKIND CORP
2023
Office Lease, dated May 10, 2017, by and between Valeritas, Inc. and RFP Lincoln 293 LLC
Lease Agreements
MANNKIND CORP
Biotechnology
MA
2023
First Amendment to Office Lease, date February 11, 2019, by and between Valeritas, Inc. and BRP 293 Equity Partners, LLC
Lease Agreements
MANNKIND CORP
Biotechnology
2023
Amendment No. 10 to the Credit and Security Agreement, dated August 29, 2022, by and among MannKind Corporation, MannKind LLC, QrumPharma, Inc., and MidCap Financial Trust
Credit Agreements
MANNKIND CORP
Biotechnology
CA
2022
Commercial Supply Agreement, dated August 12, 2021, by and between MannKind Corporation and United Therapeutics Corporation
Supply Agreements
MANNKIND CORP
2021
First Amendment to Commercial Supply Agreement, dated October 16, 2021, by and between MannKind Corporation and United Therapeutics Corporation
Supply Agreements
MANNKIND CORP
2021
Purchase and Sale Agreement, dated September 23, 2021, by and between MannKind Corporation and 1 Casper, LLC
Purchase Agreements
MANNKIND CORP
Biotechnology
FL
2021
Indenture, dated as of March 4, 2021, by and between MannKind Corporation and U.S. Bank National Association, as Trustee
Indenture Agreements
MANNKIND CORP
Biotechnology
DE
2021
Description of Common Stock
Stock Agreements
MANNKIND CORP
2021
Offer Letter, dated May 7, 2020 by and between MannKind and Alejandro Galindo
MANNKIND CORP
2021
Offer Letter, dated August 11, 2003, by and between MannKind and Joseph Kocinsky
MANNKIND CORP
Biotechnology
2021
Supply Agreement, dated as of July 31, 2014, by and between MannKind and Amphastar France Pharmaceuticals S.A.S
Supply Agreements
MANNKIND CORP
2021
Purchase Agreement, dated December 7, 2020 by and among the Company, the Acquired Company, the Sellers and the Securityholders Representative
Purchase Agreements
MANNKIND CORP
2020
Amendment No. 4 to Credit and Security Agreement, dated December 7, 2020 by and among the Company, MannKind LLC and MidCap Financial Trust
Credit Agreements
MANNKIND CORP
2020
MannKind Corporation 2018 Equity Incentive Plan, as amended
Bonus & Incentive Agreements
MANNKIND CORP
Biotechnology
DE
2020
Description of Common Stock
Stock Agreements
MANNKIND CORP
2020
Amendment to Common Stock Purchase Warrant, dated December 22, 2019, by and between MannKind Corporation and CVI Investments, Inc
Warrant Agreements
MANNKIND CORP
2019
Form of Warrant to Purchase Stock
Warrant Agreements
MANNKIND CORP
2019
Promissory Note due June 30, 2020 made by MannKind Corporation in favor of Bruce & Co., Inc., dated August 6, 2019
Note Agreements
MANNKIND CORP
2019
Promissory Note due December 31, 2020 made by MannKind Corporation in favor of Bruce & Co., Inc., dated August 6, 2019
Note Agreements
MANNKIND CORP
2019
Convertible Promissory Note made by MannKind Corporation in favor of The Mann Group LLC, dated August 6, 2019
Note Agreements
MANNKIND CORP
Biotechnology
NY
2019
Promissory Note made by MannKind Corporation in favor of The Mann Group LLC, dated August 6, 2019
Note Agreements
MANNKIND CORP
Biotechnology
NY
2019
Form of 5.75% Convertible Senior Subordinated Exchange Notes Due 2024 (included in Exhibit 4.3 as Exhibit A thereto)
Note Agreements
MANNKIND CORP
Biotechnology
DE
2019
Non-Employee Director Compensation Program
Compensation Agreements
MANNKIND CORP
2019
Fourth Amendment to Supply Agreement, dated December 24, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc
Supply Agreements
MANNKIND CORP
2019
Underwriting Agreement, dated December 19, 2018, by and between MannKind Corporation and Leerink Partners LLC, as representative of the several underwriters named therein
Underwriting Agreements
MANNKIND CORP
Biotechnology
NY
2018
Form of Common Stock Purchase Warrant
Warrant Agreements
MANNKIND CORP
Biotechnology
NY
2018
License and Collaboration Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics Corporation
Collaboration Agreements
MANNKIND CORP
2018
Research Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics Corporation
MANNKIND CORP
Biotechnology
WA
2018
Third Amendment to Supply Agreement, dated April 11, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc
Supply Agreements
MANNKIND CORP
2018
Form of Common Stock Purchase Warrant
Warrant Agreements
MANNKIND CORP
Biotechnology
2018
Offer Letter dated February 17, 2017, by and between MannKind and Courtney Barton
MANNKIND CORP
Biotechnology
2018
Offer Letter dated June 28, 2017, by and between MannKind and Patrick McCauley
MANNKIND CORP
2018
Offer Letter dated February 2, 2018, by and between MannKind and David Kendall
MANNKIND CORP
Biotechnology
2018
Non-Employee Director Compensation Program
Compensation Agreements
MANNKIND CORP
2018
Controlled Equity OfferingSM Sales Agreement, by and between MannKind and Cantor Fitzgerald & Co., dated February 27, 2018
Sales Agreements
MANNKIND CORP
2018
Indenture, by and between the Company and U.S. Bank National Association, dated October 30, 2017
Indenture Agreements
MANNKIND CORP
Biotechnology
DE
2017
OFFICE LEASE BETWEEN RUSSELL RANCH ROAD II LLC, aDelaware limited liability company, AS LANDLORD AND MANNKIND CORPORATION, a Delaware corporation AS TENANT OFFICE LEASE
Lease Agreements
MANNKIND CORP
2017
SETTLEMENT AGREEMENT
Settlement Agreements
MANNKIND CORP
Biotechnology
NY
2017
FIRST AMENDMENT TO SUPPLY AGREEMENT
Supply Agreements
MANNKIND CORP
Biotechnology
2017
SECONDAMENDMENT TO SUPPLY AGREEMENT
Supply Agreements
MANNKIND CORP
2017
FIRST AMENDMENT TO AGREEMENT OF PURCHASE AND SALE AND JOINT ESCROW INSTRUCTIONS
Escrow Agreements
MANNKIND CORP
2017
MANNKIND CORPORATION 2013 EQUITY INCENTIVE PLAN, AS AMENDED ADOPTED BY THE BOARD OFDIRECTORS: MARCH 7, 2013 APPROVED BY THESTOCKHOLDERS: MAY 23, 2013 AMENDED BYTHE BOARD: APRIL 4,...
Bonus & Incentive Agreements
MANNKIND CORP
2016
FORM OF SERIES ACOMMON STOCK PURCHASE WARRANT MANNKIND CORPORATION
Warrant Agreements
MANNKIND CORP
Biotechnology
2016
SERIES B COMMON STOCK PURCHASE WARRANT MANNKIND CORPORATION
Warrant Agreements
MANNKIND CORP
2016
MANNKIND CORPORATION WARRANT TO PURCHASE COMMON STOCK
Warrant Agreements
MANNKIND CORP
Biotechnology
DE
2016
EXHIBIT A SEPARATION DATE RELEASE (To be signed on or within 21 days after the Separation Date.)
Release Agreements
MANNKIND CORP
2016
EXHIBIT A SEPARATION DATE RELEASE (Tobe signed on or within 45 days after the Separation Date.)
Release Agreements
MANNKIND CORP
Biotechnology
CA
2016
MANNKIND CORPORATION AND U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 14, 2015 5.75% Convertible Senior Subordinated Exchange Notes due 2015 TABLE OF...
Indenture Agreements
MANNKIND CORP
2015
A-1 MANNKIND CORPORATION 5.75% Convertible Senior Subordinated Exchange Notes due 2015
Note Agreements
MANNKIND CORP
Biotechnology
2015
MANNKIND CORPORATION AND WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 10, 2015 5.75% Convertible Senior Subordinated Exchange Notes due 2018...
Indenture Agreements
MANNKIND CORP
2015
MANNKIND CORPORATION 5.75%Convertible Senior Subordinated Exchange Notes due 2018
Note Agreements
MANNKIND CORP
Biotechnology
2015
SECOND AMENDMENT TO FACILITY AGREEMENT
Facility Agreements
MANNKIND CORP
Biotechnology
NY
2014
LICENSE AND COLLABORATION AGREEMENT
Collaboration Agreements
MANNKIND CORP
2014
SUPPLY AGREEMENT
Supply Agreements
MANNKIND CORP
2014
SUPPLY AGREEMENT
Supply Agreements
MANNKIND CORP
Biotechnology
NY
2014
TRANCHE B SENIOR SECURED NOTE
Note Agreements
MANNKIND CORP
2014
AMENDED AND RESTATED SENIOR SECURED CONVERTIBLE NOTE
Note Agreements
MANNKIND CORP
Biotechnology
NY
2014
MANNKIND CORPORATION Common Stock (par value $0.01 pershare) At-The-Market Issuance Sales Agreement
Stock Agreements
MANNKIND CORP
Biotechnology
NY
2014
MANNKIND CORPORATION Common Stock (par value $0.01 pershare) At-The-Market Issuance Sales Agreement
Stock Agreements
MANNKIND CORP
2014
FIRST AMENDMENT TO FACILITY AGREEMENT AND REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreements
MANNKIND CORP
2014
MANNKIND CORPORATION Boardof Directors Compensation Program for Non-Employee Directors Updated March 25, 2013
Compensation Agreements
MANNKIND CORP
2013
MANNKIND CORPORATION WARRANT TO PURCHASE COMMON STOCK
Warrant Agreements
MANNKIND CORP
Biotechnology
NY
2013
MANNKIND CORPORATION Common Stock (par value $0.01 per share) At-The-Market Issuance Sales Agreement
Stock Agreements
MANNKIND CORP
2013
MANNKIND CORPORATION Common Stock (par value $0.01 per share) At-The-Market Issuance Sales Agreement
Stock Agreements
MANNKIND CORP
2013
40,000,000 Shares of Common Stock ($0.01 par valueper Share) and Warrants to Purchase up to 30,000,000 Shares of Common Stock MannKindCorporation UNDERWRITING AGREEMENT
Underwriting Agreements
MANNKIND CORP
2012
MANNKIND CORPORATION WARRANT TO PURCHASE COMMON STOCK
Warrant Agreements
MANNKIND CORP
2012
MANNKIND CORPORATION COMMON STOCK AND WARRANT PURCHASE AGREEMENT
Warrant Agreements
MANNKIND CORP
Biotechnology
NY
2012
AMENDED AND RESTATED PROMISSORY NOTE
Note Agreements
MANNKIND CORP
2012
AMENDMENT TO $350 MILLION AMENDED AND RESTATED PROMISSORY NOTE
Note Agreements
MANNKIND CORP
Biotechnology
NY
2012
AMENDMENT TO $350 MILLION AMENDED AND RESTATED PROMISSORY NOTE
Note Agreements
MANNKIND CORP
2012
31,250,000 Units Each Unit Consisting of One Share of Common Stock ($0.01 par value per Share) and A Warrant to Purchase 0.6 of a Share of Common Stock MannKind Corporation...
Underwriting Agreements
MANNKIND CORP
2012
MANNKIND CORPORATION WARRANT TO PURCHASE COMMON STOCK
Warrant Agreements
MANNKIND CORP
2012
MANNKIND CORPORATION COMMON STOCK PURCHASE AGREEMENT
Stock Agreements
MANNKIND CORP
Biotechnology
NY
2012
AMENDMENT TO $350 MILLION AMENDED AND RESTATED PROMISSORY NOTE
Note Agreements
MANNKIND CORP
Biotechnology
NY
2012
EX-101 INSTANCE DOCUMENT
MANNKIND CORP
Biotechnology
CA
2011
EX-101 INSTANCE DOCUMENT
MANNKIND CORP
2011
MANNKIND CORPORATION (A Delaware corporation) 9,000,000 Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreements
MANNKIND CORP
Biotechnology
NY
2010
MANNKIND CORPORATION AND WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 24, 2010 5.75% Convertible Senior Notes due 2015
Indenture Agreements
MANNKIND CORP
2010
[FORM OF FACE OF NOTE] [INCLUDE IF A GLOBAL NOTE]
Note Agreements
MANNKIND CORP
2010
COMMON STOCK PURCHASE AGREEMENT
Stock Agreements
MANNKIND CORP
Biotechnology
NY
2010
OMNI CAPITAL CORPORATION 119 West 72nd Street Suite 283 33 West Main Street POB 390New York, NY 10023 Oyster Bay, NY 11771 Mr. Matthew J. Pfeffer August 10, 2010Chief Financial...
MANNKIND CORP
2010
MANNKIND CORPORATION COMMON STOCK PURCHASE AGREEMENT
Stock Agreements
MANNKIND CORP
2010
AMENDED AND RESTATED PROMISSORY NOTE $350,000,000 Dated August 10, 2010 Valencia, California
Note Agreements
MANNKIND CORP
Biotechnology
NY
2010
7,400,000 Shares
MANNKIND CORP
2009
Current assets
MANNKIND CORP
2009
Current assets
MANNKIND CORP
Biotechnology
DE
2009
the risk of severe hypoglycemia, which is abnormally low levels of blood glucose that result from excessive insulin administration. Hypoglycemia can result in loss of mental...
Administration Agreements
MANNKIND CORP
2008
Current assets
MANNKIND CORP
2007
PROMISSORY NOTE $150,000,000 August 1, 2007 Valencia, California
Note Agreements
MANNKIND CORP
Biotechnology
CA
2007
MANNKIND CORPORATION Issuer And WELLS FARGO BANK, N.A. Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 12, 2006
Indenture Agreements
MANNKIND CORP
2006
MANNKIND CORPORATION
MANNKIND CORP
Biotechnology
NY
2006
MANNKIND CORPORATION
MANNKIND CORP
2006
Current assets
MANNKIND CORP
Biotechnology
2006
Current assets
MANNKIND CORP
2006
MannKind Corporation Officers Incentive Program
Bonus & Incentive Agreements
MANNKIND CORP
Biotechnology
2006
MannKind Corporation 2004 Non-Employee Directors Stock Option Plan Adopted March 23, 2004 Approved by Stockholders March 23, 2004 Effective Date: August 2, 2004
Stock Agreements
MANNKIND CORP
2006
Supply Agreement dated December 31, 2004 between MannKind Corporation and Vaupell, Inc
Supply Agreements
MANNKIND CORP
Biotechnology
DE
2005
Pro forma
MANNKIND CORP
Biotechnology
DE
2004
Consent of Deloitte & Touche LLP
MANNKIND CORP
Biotechnology
2004
2004 Equity Incentive & Stock Option Agreement
Bonus & Incentive Agreements
MANNKIND CORP
Biotechnology
DE
2004
2004 Non-Employee Directors' Stock Option Plan
Stock Agreements
MANNKIND CORP
Biotechnology
CA
2004
2004 Employee Stock Purchase & Offering Document
Stock Agreements
MANNKIND CORP
2004
Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes....
Release Agreements
MANNKIND CORP
2004
Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes....
Release Agreements
MANNKIND CORP
2004
Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes....
Release Agreements
MANNKIND CORP
2004
Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes....
Release Agreements
MANNKIND CORP
2004
Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes....
Release Agreements
MANNKIND CORP
2004
Approximates natural first-phase insulin release spike. Typically, regular insulin delivered by subcutaneous injection results in peak insulin levels in about 120 to 180 minutes....
Release Agreements
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004
Technosphere Insulin approximation
MANNKIND CORP
2004